Stoke Therapeutics Inc. (STOK): Price and Financial Metrics

Stoke Therapeutics Inc. (STOK): $16.25

1.27 (-7.25%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

C

Add STOK to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#213 of 351

in industry

STOK Price/Volume Stats

Current price $16.25 52-week high $17.58
Prev. close $17.52 52-week low $3.35
Day low $16.00 Volume 709,300
Day high $17.34 Avg. volume 908,007
50-day MA $13.43 Dividend yield N/A
200-day MA $7.34 Market Cap 846.95M

STOK Stock Price Chart Interactive Chart >


Stoke Therapeutics Inc. (STOK) Company Bio


Stoke Therapeutics, Inc. was founded in 2014 by Professor Adrian Krainer, PhD. and Isabel Aznarez, PhD to research and develop treatments for the underlying cause of genetic diseases. The company focuses on developing antisense oligonucleotide medicines that increase gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver, and kidney. Stoke’s proprietary platform, Targeted Augmentation of Nuclear Gene Output (TANGO) allows for the delivery of disease-modifying therapies in a precise and controlled manner. Edward M. Kaye, M.D., currently serves as the company’s director and Chief Executive Officer.


STOK Latest News Stream


Event/Time News Detail
Loading, please wait...

STOK Latest Social Stream


Loading social stream, please wait...

View Full STOK Social Stream

Latest STOK News From Around the Web

Below are the latest news stories about STOKE THERAPEUTICS INC that investors may wish to consider to help them evaluate STOK as an investment opportunity.

Wall Street Analysts Predict a 220.81% Upside in Stoke Therapeutics, Inc. (STOK): Here's What You Should Know

The consensus price target hints at a 220.8% upside potential for Stoke Therapeutics, Inc. (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | December 14, 2023

Is Stoke Therapeutics (NASDAQ:STOK) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Yahoo | December 12, 2023

Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting

BEDFORD, Mass., December 01, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations of clinical data at the American Epilepsy Society (AES) 2023 Annual Meeting December 1 – 5, in Orlando, Florida. Together, these data support the company’s continued progress to develop STK-001 as the first disease-modifying medi

Yahoo | December 1, 2023

Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting

BEDFORD, Mass., November 21, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that presentations related to the Company’s work in Dravet syndrome will be presented at the American Epilepsy Society (AES) 2023 Annual Meeting, taking place December 1 – 5, in Orlando, Florida. The company is advancing STK-001 as potentially the first medic

Yahoo | November 21, 2023

Stoke Therapeutics Inc (STOK) Reports Q3 Financial Results and Progress in Dravet Syndrome Treatment

Key Developments in STK-001 Studies and Financial Health Indicators

Yahoo | November 9, 2023

Read More 'STOK' Stories Here

STOK Price Returns

1-mo 15.82%
3-mo 154.30%
6-mo 222.10%
1-year 25.00%
3-year -55.77%
5-year N/A
YTD 208.94%
2023 -43.01%
2022 -61.53%
2021 -61.26%
2020 118.68%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!